Single-cell tracking of flavivirus RNA uncovers species-specific interactions with the immune system dictating disease outcome

Nature Communications

Volumn 8, Issue , 2017, Pages

  Douam, Florian ^a   Hrebikova, Gabriela ^a   Albrecht, Yentli E Soto ^a   Sellau, Julie ^a   Sharon, Yael ^a   Ding, Qiang ^a   Ploss, Alexander ^a  

^a PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; STAT1 PROTEIN; VIRUS RNA; CYTOKINE;

CELLS AND CELL COMPONENTS; DISEASE INCIDENCE; DISEASE TREATMENT; IMMUNE SYSTEM; RNA; VIRULENCE; VIRUS; YELLOW FEVER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COMPARTMENTALIZATION; CELL INTERACTION; CELL SUBPOPULATION; CELL TRACKING; CONTROLLED STUDY; FLAVIVIRUS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INTERACTIONS WITH RNA; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; RNA HYBRIDIZATION; RNA VIRUS; SINGLE CELL TRACKING; SPECIES DIFFERENCE; VIREMIA; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS VIRULENCE; YELLOW FEVER VIRUS; ANIMAL; CD8+ T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; GENETICS; HEK293 CELL LINE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MALE; METABOLISM; SINGLE CELL ANALYSIS; VIROLOGY; XENOGRAFT; YELLOW FEVER;

FLAVIVIRUS; MURINAE; RNA VIRUSES; YELLOW FEVER VIRUS;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; FLAVIVIRUS; FLOW CYTOMETRY; HEK293 CELLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MICE; RNA, VIRAL; SINGLE-CELL ANALYSIS; SPECIES SPECIFICITY; TRANSPLANTATION, HETEROLOGOUS; YELLOW FEVER; YELLOW FEVER VIRUS;

EID: 85015216333     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14781     Document Type: Article

References (58)

1. Butler, D. Fears rise over yellow fevers next move. Nature 532, 155-156 (2016).
2. Kupferschmidt, K. Infectious diseases. Yellow fever outbreak triggers vaccine alarm. Science 352, 128-129 (2016).
3. Haug, C. J., Kieny, M. P. & Murgue, B. The Zika challenge. N. Engl. J. Med. 374, 1801-1803 (2016).
4. Sharp, P. M. & Hahn, B. H. Origins of HIV and the AIDS pandemic. Csh Perspect. Med. 1, a006841 (2011).
5. Wandeler, G., Dufour, J. F., Bruggmann, P. & Rauch, A. Hepatitis C: A changing epidemic. Swiss Med. Wkly 145, w14093 (2015).
6. Bhatt, S. et al. The global distribution and burden of dengue. Nature 496, 504-507 (2013).
7. Douam, F. et al. Genetic dissection of the host tropism of human-Tropic pathogens. Annu. Rev. Genet. 49, 21-45 (2015).
8. Rall, G. F., Lawrence, D. M. & Patterson, C. E. The application of transgenic and knockout mouse technology for the study of viral pathogenesis. Virology 271, 220-226 (2000).
9. Shultz, L. D., Brehm, M. A., Garcia-Martinez, J. V. & Greiner, D. L. Humanized mice for immune system investigation: progress, promise and challenges. Nat. Rev. Immunol. 12, 786-798 (2012).
10. Gaska, J. M. & Ploss, A. Study of viral pathogenesis in humanized mice. Curr. Opin. Virol. 11, 14-20 (2015).
11. Babcock, G. J., Decker, L. L., Volk, M. & Thorley-Lawson, D. A. EBV persistence in memory B cells in vivo. Immunity 9, 395-404 (1998).
12. Hazenberg, M. D., Hamann, D., Schuitemaker, H. & Miedema, F. T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat. Immunol. 1, 285-289 (2000).
13. Schmid, M. A., Diamond, M. S. & Harris, E. Dendritic cells in dengue virus infection: Targets of virus replication and mediators of immunity. Front. Immunol. 5, 647 (2014).
14. Cong, Y. et al. Characterization of yellow fever virus infection of human and non-human primate antigen presenting cells and their interaction with CD4(+) T cells. PLoS Neglected Trop. Dis. 10, e0004709 (2016).
15. Bowie, A. G. & Unterholzner, L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat. Rev. Immunol. 8, 911-922 (2008).
16. Porichis, F. et al. High-Throughput detection of miRNAs and gene-specific mRNA at the single-cell level by flow cytometry. Nat. Commun. 5, 5641 (2014).
17. Monath, T. P. & Vasconcelos, P. F. Yellow fever. J. Clin. Virol. 64, 160-173 (2014).
18. Hahn, C. S., Dalrymple, J. M., Strauss, J. H. & Rice, C. M. Comparison of the virulent Asibi strain of yellow-fever virus with the 17D vaccine strain derived from it. Proc. Natl Acad. Sci. USA 84, 2019-2023 (1987).
19. Theiler, M. & Smith, H. H. The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 65, 787-800 (1937).
20. Bonaldo, M. C., Sequeira, P. C. & Galler, R. The yellow fever 17D virus as a platform for new live attenuated vaccines. Hum. Vaccines Immunotherap. 10, 1256-1265 (2014).
21. Quaresma, J. A., Pagliari, C., Medeiros, D. B., Duarte, M. I. & Vasconcelos, P. F. Immunity and immune response, pathology and pathologic changes: progress and challenges in the immunopathology of yellow fever. Rev. Med. Virol. 23, 305-318 (2013).
22. Monath, T. P. Treatment of yellow fever. Antiviral Res. 78, 116-124 (2008).
23. ter Meulen, J. et al. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J. Infect. Dis. 190, 1821-1827 (2004).
24. Theiler, M. Susceptibility of white mice to the virus of yellow fever. Science 71, 367 (1930).
25. Julander, J. G. Animal models of yellow fever and their application in clinical research. Curr. Opin. Virol. 18, 64-69 (2016).
26. Jiang, X., Dalebout, T. J., Lukashevich, I. S., Bredenbeek, P. J. & Franco, D. Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone. J. Gen. Virol. 96, 804-814 (2015).
27. Meier, K. C., Gardner, C. L., Khoretonenko, M. V., Klimstra, W. B. & Ryman, K. D. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathogen 5, e1000614 (2009).
28. Thibodeaux, B. A. et al. A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain. Vaccine 30, 3180-3187 (2012).
29. Billerbeck, E. et al. Characterization of human antiviral adaptive immune responses during hepatotropic virus infection in HLA-Transgenic human immune system mice. J. Immunol. 191, 1753-1764 (2013).
30. Billerbeck, E. et al. Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rgamma(null) humanized mice. Blood 117, 3076-3086 (2011).
31. Billerbeck, E. et al. Insufficient interleukin-12 signalling favours differentiation of human CD4(+) and CD8(+) T cells into GATA-3(+) and GATA-3(+) T-bet(+) subsets in humanized mice. Immunology 143, 202-218 (2014).
32. Chan, K. R. et al. Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity. Nat. Microbiol. 1, 16164 (2016).
33. Reinhardt, B., Jaspert, R., Niedrig, M., Kostner, C. & LAge-Stehr, J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: A model of human flavivirus infection. J. Med. Virol. 56, 159-167 (1998).
34. Strowig, T. et al. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J. Exp. Med. 206, 1423-1434 (2009).
35. Traggiai, E. et al. Development of a human adaptive immune system in cord blood cell-Transplanted mice. Science 304, 104-107 (2004).
36. Brown, C. Zika virus outbreaks in Asia and South America. Can. Med. Assoc. J. 188, E34 (2016).
37. Garcia, E. et al. Zika virus infection: global update on epidemiology and potentially associated clinical manifestations. Wkly Epidemiol. Record/Health Sect. Secretariat League Nations 91, 73-81 (2016).
38. Mestas, J. & Hughes, C. C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731-2738 (2004).
39. Tisoncik, J. R. et al. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 76, 16-32 (2012).
40. Lee, Y. R. et al. MCP-1, a highly expressed chemokine in dengue haemorrhagic fever/dengue shock syndrome patients, may cause permeability change, possibly through reduced tight junctions of vascular endothelium cells. J. Gen. Virol. 87, 3623-3630 (2006).
41. Engelmann, F. et al. Pathophysiologic and transcriptomic analyses of viscerotropic yellow fever in a rhesus macaque model. PLoS Negl. Trop. Dis. 8, e3295 (2014).
42. Barba-Spaeth, G., Longman, R. S., Albert, M. L. & Rice, C. M. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J. Exp. Med. 202, 1179-1184 (2005).
43. Jenkins, M. R. et al. Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J. Exp. Med. 212, 307-317 (2015).
44. Pennock, N. D. et al. T cell responses: naive to memory and everything in between. Adv. Physiol. Educ. 37, 273-283 (2013).
45. Laurent-Rolle, M. et al. The interferon signaling antagonist function of yellow fever virus NS5 protein is activated by type I interferon. Cell Host Microbe 16, 314-327 (2014).
46. Munoz-Jordan, J. L. et al. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J. Virol. 79, 8004-8013 (2005).
47. Bruni, D. et al. Viral entry route determines how human plasmacytoid dendritic cells produce type I interferons. Sci. Signal. 8, ra25 (2015).
48. Swiecki, M. & Colonna, M. The multifaceted biology of plasmacytoid dendritic cells. Nat. Rev. Immunol. 15, 471-485 (2015).
49. Burstein, H. J. & Abbas, A. K. T-cell-mediated activation of B cells. Curr. Opin. Immunol. 3, 345-349 (1991).
50. Mooney, N. A. et al. Lymphocyte activation via MHC class II antigens. Nouvelle Revue Francaise Dhematol. 32, 53-57 (1990).
51. Marquardt, N. et al. The human NK cell response to yellow fever virus 17D is primarily governed by NK cell differentiation independently of NK cell education. J. Immunol. 195, 3262-3272 (2015).
52. Rydyznski, C. E. & Waggoner, S. N. Boosting vaccine efficacy the natural (killer) way. Trends Immunol. 36, 536-546 (2015).
53. Theocharides, A. P., Rongvaux, A., Fritsch, K., Flavell, R. A. & Manz, M. G. Humanized hemato-lymphoid system mice. Haematologica 101, 5-19 (2016).
54. Brehm, M. A. et al. Parameters for establishing humanized mouse models to study human immunity: Analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation. Clin. Immunol. 135, 84-98 (2010).
55. Ogilvy, S. et al. Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. Blood 94, 1855-1863 (1999).
56. Postic, C. et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J. Biol. Chem. 274, 305-315 (1999).
57. Klover, P. J. et al. Loss of STAT1 from mouse mammary epithelium results in an increased neu-induced tumor burden. Neoplasia 12, 899-905 (2010).
58. Khromykh, A. A., Varnavski, A. N., Sedlak, P. L. & Westaway, E. G. Coupling between replication and packaging of flavivirus RNA: evidence derived from the use of DNA-based full-length cDNA clones of Kunjin virus. J. Virol. 75, 4633-4640 (2001).